Jérôme Parcq July 2023 Press Release Op2Lysis was awarded a Deeptech Development Grant (ADD) to manufacture the clinical batch of OptPA, the active substance in O2L-001, for phase 1/2 in patients suffering from cerebral haemorrhage. The press release: ADD-press-release-June-2023-ENTélécharger
